Press Releases Latest May 31, 2022 Theratechnologies Announces New Head of Investor Relations Press Releases Year None2022202120202019201820172016201520142013 Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers Nov 23, 2020 Theratechnologies To Present At The Piper Sandler Virtual Healthcare Conference Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH Nov 06, 2020 Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020 First page « Previous page ‹ … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page › Last page » Displaying 51 - 60 of 281
Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers
Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH
Nov 06, 2020 Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020
